Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.

Yayun Liang, Manal A. Eid, Fathy El Etreby, Ronald W Lewis, M. Vijay Kumar

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Successful therapy should induce apoptosis in prostate cancer cells irrespective of their androgen response. We have investigated the possibility of utilizing Mifepristone and Tamoxifen as treatment options for prostate cancer cells. Because preliminary results demonstrated induction of apoptosis by these drugs, the mechanism of induction of apoptosis was investigated. LNCaP-C4 prostate cancer cells were treated with Mifepristone and/or Tamoxifen. To confirm cytotoxic effects, nude mice with LNCaP-C4 xenografts were treated with Mifepristone and Tamoxifen. Cell viability was assayed using Sulforhodamine B (SRB) assay and DNA fragmentation was measured by ELISA. Culture media from vehicle- and drug-treated cells were collected and secretion of transforming growth factor beta1 (TGFbeta1) was estimated by ELISA. Role of TGFbeta1 was confirmed by inhibiting its function using TGFbeta1 antibody or M6P, which blocked activation of TGFbeta1. Apoptotic effects were determined by immunoblots of cytochrome c levels in cytosol and by in vitro colorimetric assay of caspase-3 activity. Results showed that although both drugs induced apoptosis in LNCaP-C4 cells, Mifepristone was more effective. The effects of these drugs on xenografts confirmed in vitro results. It was hypothesized that drug-induced secretion of TGFbeta1 may be responsible for induction of apoptosis. Neutralization of TGFbeta1 with an antibody or blocking the activation of TGFbeta1 by M6P abrogated the effects of Mifepristone and Tamoxifen confirming our hypothesis. Furthermore, treatment with Mifepristone and/or Tamoxifen released cytochrome c into the cytoplasm and induced activity of caspase-3, providing evidence that the drug-stimulated secretion of TGFbeta1 was responsible for induction of apoptosis in these cells. In conclusion, both Mifepristone and Tamoxifen induced apoptosis mediated through TGFbeta1. However, no critical advantage was noted by the addition of Tamoxifen to Mifepristone treatment.

Original languageEnglish (US)
Pages (from-to)1259-1267
Number of pages9
JournalInternational Journal of Oncology
Volume21
Issue number6
StatePublished - Jan 1 2002

Fingerprint

Transforming Growth Factor beta1
Mifepristone
Prostatic Neoplasms
Tamoxifen
Apoptosis
Pharmaceutical Preparations
Cytochromes c
lissamine rhodamine B
Heterografts
Caspase 3
Enzyme-Linked Immunosorbent Assay
Blocking Antibodies
DNA Fragmentation
Therapeutics
Nude Mice
Cytosol
Androgens
Culture Media
Cell Survival
Cytoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liang, Y., Eid, M. A., El Etreby, F., Lewis, R. W., & Kumar, M. V. (2002). Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. International Journal of Oncology, 21(6), 1259-1267.

Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. / Liang, Yayun; Eid, Manal A.; El Etreby, Fathy; Lewis, Ronald W; Kumar, M. Vijay.

In: International Journal of Oncology, Vol. 21, No. 6, 01.01.2002, p. 1259-1267.

Research output: Contribution to journalArticle

Liang, Y, Eid, MA, El Etreby, F, Lewis, RW & Kumar, MV 2002, 'Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.', International Journal of Oncology, vol. 21, no. 6, pp. 1259-1267.
Liang, Yayun ; Eid, Manal A. ; El Etreby, Fathy ; Lewis, Ronald W ; Kumar, M. Vijay. / Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. In: International Journal of Oncology. 2002 ; Vol. 21, No. 6. pp. 1259-1267.
@article{a6d951811fd14f09832e20e518c45505,
title = "Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.",
abstract = "Successful therapy should induce apoptosis in prostate cancer cells irrespective of their androgen response. We have investigated the possibility of utilizing Mifepristone and Tamoxifen as treatment options for prostate cancer cells. Because preliminary results demonstrated induction of apoptosis by these drugs, the mechanism of induction of apoptosis was investigated. LNCaP-C4 prostate cancer cells were treated with Mifepristone and/or Tamoxifen. To confirm cytotoxic effects, nude mice with LNCaP-C4 xenografts were treated with Mifepristone and Tamoxifen. Cell viability was assayed using Sulforhodamine B (SRB) assay and DNA fragmentation was measured by ELISA. Culture media from vehicle- and drug-treated cells were collected and secretion of transforming growth factor beta1 (TGFbeta1) was estimated by ELISA. Role of TGFbeta1 was confirmed by inhibiting its function using TGFbeta1 antibody or M6P, which blocked activation of TGFbeta1. Apoptotic effects were determined by immunoblots of cytochrome c levels in cytosol and by in vitro colorimetric assay of caspase-3 activity. Results showed that although both drugs induced apoptosis in LNCaP-C4 cells, Mifepristone was more effective. The effects of these drugs on xenografts confirmed in vitro results. It was hypothesized that drug-induced secretion of TGFbeta1 may be responsible for induction of apoptosis. Neutralization of TGFbeta1 with an antibody or blocking the activation of TGFbeta1 by M6P abrogated the effects of Mifepristone and Tamoxifen confirming our hypothesis. Furthermore, treatment with Mifepristone and/or Tamoxifen released cytochrome c into the cytoplasm and induced activity of caspase-3, providing evidence that the drug-stimulated secretion of TGFbeta1 was responsible for induction of apoptosis in these cells. In conclusion, both Mifepristone and Tamoxifen induced apoptosis mediated through TGFbeta1. However, no critical advantage was noted by the addition of Tamoxifen to Mifepristone treatment.",
author = "Yayun Liang and Eid, {Manal A.} and {El Etreby}, Fathy and Lewis, {Ronald W} and Kumar, {M. Vijay}",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
pages = "1259--1267",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.

AU - Liang, Yayun

AU - Eid, Manal A.

AU - El Etreby, Fathy

AU - Lewis, Ronald W

AU - Kumar, M. Vijay

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Successful therapy should induce apoptosis in prostate cancer cells irrespective of their androgen response. We have investigated the possibility of utilizing Mifepristone and Tamoxifen as treatment options for prostate cancer cells. Because preliminary results demonstrated induction of apoptosis by these drugs, the mechanism of induction of apoptosis was investigated. LNCaP-C4 prostate cancer cells were treated with Mifepristone and/or Tamoxifen. To confirm cytotoxic effects, nude mice with LNCaP-C4 xenografts were treated with Mifepristone and Tamoxifen. Cell viability was assayed using Sulforhodamine B (SRB) assay and DNA fragmentation was measured by ELISA. Culture media from vehicle- and drug-treated cells were collected and secretion of transforming growth factor beta1 (TGFbeta1) was estimated by ELISA. Role of TGFbeta1 was confirmed by inhibiting its function using TGFbeta1 antibody or M6P, which blocked activation of TGFbeta1. Apoptotic effects were determined by immunoblots of cytochrome c levels in cytosol and by in vitro colorimetric assay of caspase-3 activity. Results showed that although both drugs induced apoptosis in LNCaP-C4 cells, Mifepristone was more effective. The effects of these drugs on xenografts confirmed in vitro results. It was hypothesized that drug-induced secretion of TGFbeta1 may be responsible for induction of apoptosis. Neutralization of TGFbeta1 with an antibody or blocking the activation of TGFbeta1 by M6P abrogated the effects of Mifepristone and Tamoxifen confirming our hypothesis. Furthermore, treatment with Mifepristone and/or Tamoxifen released cytochrome c into the cytoplasm and induced activity of caspase-3, providing evidence that the drug-stimulated secretion of TGFbeta1 was responsible for induction of apoptosis in these cells. In conclusion, both Mifepristone and Tamoxifen induced apoptosis mediated through TGFbeta1. However, no critical advantage was noted by the addition of Tamoxifen to Mifepristone treatment.

AB - Successful therapy should induce apoptosis in prostate cancer cells irrespective of their androgen response. We have investigated the possibility of utilizing Mifepristone and Tamoxifen as treatment options for prostate cancer cells. Because preliminary results demonstrated induction of apoptosis by these drugs, the mechanism of induction of apoptosis was investigated. LNCaP-C4 prostate cancer cells were treated with Mifepristone and/or Tamoxifen. To confirm cytotoxic effects, nude mice with LNCaP-C4 xenografts were treated with Mifepristone and Tamoxifen. Cell viability was assayed using Sulforhodamine B (SRB) assay and DNA fragmentation was measured by ELISA. Culture media from vehicle- and drug-treated cells were collected and secretion of transforming growth factor beta1 (TGFbeta1) was estimated by ELISA. Role of TGFbeta1 was confirmed by inhibiting its function using TGFbeta1 antibody or M6P, which blocked activation of TGFbeta1. Apoptotic effects were determined by immunoblots of cytochrome c levels in cytosol and by in vitro colorimetric assay of caspase-3 activity. Results showed that although both drugs induced apoptosis in LNCaP-C4 cells, Mifepristone was more effective. The effects of these drugs on xenografts confirmed in vitro results. It was hypothesized that drug-induced secretion of TGFbeta1 may be responsible for induction of apoptosis. Neutralization of TGFbeta1 with an antibody or blocking the activation of TGFbeta1 by M6P abrogated the effects of Mifepristone and Tamoxifen confirming our hypothesis. Furthermore, treatment with Mifepristone and/or Tamoxifen released cytochrome c into the cytoplasm and induced activity of caspase-3, providing evidence that the drug-stimulated secretion of TGFbeta1 was responsible for induction of apoptosis in these cells. In conclusion, both Mifepristone and Tamoxifen induced apoptosis mediated through TGFbeta1. However, no critical advantage was noted by the addition of Tamoxifen to Mifepristone treatment.

UR - http://www.scopus.com/inward/record.url?scp=1842514450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842514450&partnerID=8YFLogxK

M3 - Article

C2 - 12429976

AN - SCOPUS:1842514450

VL - 21

SP - 1259

EP - 1267

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -